Genflow Biosciences PLC Announces Strategic Technology Collaboration

 Genflow Biosciences Plc is a European biotechnology company focused on the development of gene therapies for age-related diseases. It announces a strategic technology collaboration with Acuitas Therapeutics ("Acuitas"), a globally recognised leader in lipid nanoparticle ("LNP") delivery systems, whose technology has underpinned therapeutic programmes for mRNA brought to market. 

This company is publicly listed on the London Stock Exchange under the ticker symbol GENF. It operates in the biotechnology sector, focusing on the development of gene therapies to address age-related decline. 

According to Towards Healthcare, the Drug Delivery Nanoparticles Formulation Market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 105.38 billion in 2026 to approximately USD 337.31 billion by 2035, representing a compound annual growth rate (CAGR) of 13.8% from 2026 to 2035. Growth is driven by the rising prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular conditions, which in turn drives the demand for efficient drug delivery systems. This increasing demand for targeted therapies that can effectively treat specific diseases is being met by nanoparticles, which can help achieve these goals. 

About Acuitas Therapeutics 

Acuitas Therapeutics Inc. is the global leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics. It collaborates with pharmaceutical and biotech companies, academic researchers, and global health organisations to advance a broad range of medicines for a variety of diseases. 

It is advancing next-generation LNP to support a variety of modalities. These therapies include targeted LNP for extrahepatic and in vivo CAR-T cell therapies, epigenetic medicines to modulate gene expression without altering DNA, multivalent infectious disease vaccines, as well as oncology vaccines, including personalised cancer vaccines. 

Chief Executive Officer of Genflow Biosciences, Eric Leire, committed their own resources to work with our science, which is a powerful endorsement of what we are building and for shareholders, we are gaining access to world-class, clinically proven delivery technology at no cost and with no dilution. This is kind of capital-efficient, high-impact collaboration that de-risks the pipeline, strengthens our partnering position, and accelerates our path towards clinical development. 

A recent report by Towards Healthcare highlights that the Drug Delivery Nanoparticles Formulation Market is witnessing growth due to the market being characterised by high R&D intensity and the investment of major pharmaceutical and biotech firms in nanoparticle-based formulations to enhance drug efficacy and reduce side effects. It transitions from niche applications to mainstream therapeutic solutions, underscoring its strategic importance for future healthcare delivery. 

The North America region is dominated by strong biotech R&D investment and billions in federal nanotechnology funding. The Asia Pacific is driven by increasing healthcare investments, expanding pharmaceutical manufacturing, and rising prevalence of chronic diseases.